KIRYAT ONO, Israel & NEW YORK--(BUSINESS WIRE)--GammaCan International, Inc. (“GammaCan” or “the Company”) (OTCBB: GCAN), a developer of proprietary immunotherapies for the treatment of melanoma and other cancers, today announced progress in its VitiGam™ development program. During the last several months, the Company has completed a series of significant animal experiments confirming the effectiveness of IgG preparations derived from vitiligo donors against melanoma cells. This is the basis for GammaCan’s lead product, VitiGam™.
